Lantus Injection, Solution
Product Images NDC 0088-2220

Product Visual Gallery

This gallery contains 36 technical images submitted to the FDA as part of the official labeling for Lantus (NDC 0088-2220). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Sanofi-aventis U.s. Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Lantus 01)

A line chart comparing glucose infusion rate (mg/kg/min) over time (hours) after subcutaneous injection for Lantus (insulin glargine) and NPH insulin. Lantus shows a relatively steady glucose infusion rate over 24 hours, while NPH insulin peaks sharply around 4-6 hours then declines. The chart includes legend details and marks the end of the observation period at 24 hours.*

FDA Label Image

Figure 1 (Lantus 02)

An instructional drawing showing hands removing a cap from a small vial bottle, typically used for injectable solutions. The image suggests handling steps for preparing an injection but does not include text or additional context.*

FDA Label Image

Figure (Lantus 03)

An instructional line drawing showing hands removing a protective foil seal from the top of a vial, illustrating part of the preparation for using a vial-based injection solution.*

FDA Label Image

Figure (Lantus 04)

An instructional illustration showing a close-up of hands holding a syringe and a pen-type injection device, indicating the process of preparing or injecting the medication. The image likely demonstrates how to attach or operate the injection mechanism for subcutaneous administration.*

FDA Label Image

Figure (Lantus 05)

An instructional illustration showing a person drawing medication from a vial into a syringe, demonstrating proper injection preparation technique for subcutaneous administration.*

FDA Label Image

Figure (Lantus 06)

An instructional black-and-white line drawing depicting a hand holding a syringe. The illustration shows the thumb pressing the plunger downward, likely indicating the step to expel air or administer the injection. No text or branding visible.*

FDA Label Image

Figure (Lantus 07)

An instructional diagram showing a hand holding a vial and inserting a syringe into it, with an arrow indicating the direction to pull the syringe plunger, representing the process of drawing insulin solution for injection.*

FDA Label Image

Figure (Lantus 08)

An instructional diagram illustrating recommended injection sites for subcutaneous administration, highlighting the upper arms, stomach, and thighs on a human figure.*

FDA Label Image

Figure (Lantus 09)

An instructional illustration showing a human hand holding a small device or vial near a finger, demonstrating a subcutaneous injection technique, possibly for Lantus (insulin glargine) injection solution.*

FDA Label Image

Figure (Lantus 10)

An instructional illustration showing a person administering a subcutaneous injection into the finger with a syringe. The image highlights correct hand placement and injection technique, likely related to using Lantus insulin glargine injection solution for subcutaneous use.*

FDA Label Image

Figure (Lantus 11)

An instructional diagram showing preferred subcutaneous injection sites on a human body. Highlighted areas include the upper arms, stomach, and thighs, indicating common locations for administering subcutaneous injections such as insulin glargine (Lantus).*

FDA Label Image

Figure (Lantus 12)

An illustration diagram showing the components of a Lantus SoloStar injection pen for insulin glargine 100 IU/mL. It depicts the pen cap, pen needle parts (outer needle cap, inner needle cap, protective seal, needle), and the pen body with labeled features including the insulin reservoir, rubber seal, dose window, dosage selector, and injection button.*

FDA Label Image

Figure (Lantus 13)

Lantus Solostar insulin glargine injection pen for subcutaneous use with 100 units per mL strength. The label indicates it is for single patient use only. The product is manufactured by sanofi-aventis U.S. LLC.*

FDA Label Image

Figure (Lantus 14)

Lantus 100 IU/mL injection solution pen for subcutaneous use by sanofi-aventis U.S. LLC. The label on the pen displays a lot number (123XY) and an expiration date (2029-10-31), along with a black and white QR code and a purple indicator band near the pen's top cap.*

FDA Label Image

Figure (Lantus 15)

An instructional illustration showing the proper handling of a Lantus insulin glargine injection pen. It depicts a hand holding the pen with the dose selector visible on the left, and the same hand pressing the injection button on the right, indicated by a blue arrow pointing right. The diagram emphasizes the technique for using the subcutaneous injection device.*

FDA Label Image

Figure (Lantus 16)

Lantus Solostar insulin glargine injection pen label showing 100 units/mL strength. The product is for subcutaneous use and intended for single patient use only. The image includes a zoomed-in view of the dosage dial on the injection pen, marked in units up to 260, used to set the insulin dose. Labeler is sanofi-aventis U.S. LLC.*

FDA Label Image

Figure (Lantus 17)

An instructional illustration showing hands holding a prefilled syringe pen device, with one hand wiping the pen's needle cover with an alcohol swab. This depicts preparation steps for subcutaneous injection of Lantus (insulin glargine) solution.*

FDA Label Image

Figure (Lantus 18)

An instructional illustration showing two hands removing the cap from a syringe or pen needle. The image emphasizes proper handling technique, with one hand holding the syringe or pen and the other hand pulling off the protective cap from the needle end.*

FDA Label Image

Figure (Lantus 19)

An instructional diagram showing a hand holding a Lantus insulin glargine injection pen. The illustration demonstrates twisting off the protective cap with blue arrows indicating the correct twisting direction, and a red circle warning against pulling the cap straight off. The pen is detailed with a visible dosage dial and needle cover.*

FDA Label Image

Principal Display Panel (10 mL Vial Carton)

An instructional illustration showing the proper technique for removing the protective cap from a Lantus insulin glargine 100 U/mL injection pen prior to subcutaneous administration.*

FDA Label Image

Principal Display Panel (3 mL Pen Carton)

An instructional illustration showing a hand removing a cap from a jar and another hand holding a syringe. The syringe appears prepared for use, indicating a step in medication preparation or administration.*

FDA Label Image

Lantus 22

An instructional illustration showing hands holding a Lantus insulin glargine injection pen. The image depicts dialing the dose by turning the dose selector, with a close-up inset highlighting the dose window displaying the selected insulin units.*

FDA Label Image

Lantus 23

An instructional illustration showing a person holding a syringe filled with medication. A close-up inset displays liquid being expelled from the syringe needle, demonstrating priming or removing air bubbles before injection.*

FDA Label Image

Lantus 24

Lantus SoloStar prefilled insulin pen for injection, containing insulin glargine at 100 units per mL. The pen is designed for subcutaneous administration, labeled for single patient use only, and manufactured by sanofi-aventis U.S. LLC. The image shows the pen body with a dose selector on the end and a needle attached.*

FDA Label Image

Lantus 25

An instructional illustration depicts hands preparing a Lantus insulin glargine injection pen for subcutaneous use. The image shows twisting the pen cap to remove it, indicated by a blue arrow, with visible dosage markings on the pen barrel.*

FDA Label Image

Lantus 26

An instructional diagram showing a close-up view of a dosing selector on an injection device displaying '20 units selected'. This image illustrates setting the dose for a subcutaneous injection of a medication like insulin glargine (Lantus).*

FDA Label Image

Lantus 27

An illustration showing a close-up of a dosing dial window with the year 2022 displayed, indicating the selection of 21 units, likely related to dosage setting on an insulin injection device for Lantus (insulin glargine) 100 units/mL subcutaneous injection.*

FDA Label Image

Lantus 28

An instructional illustration showing a hand holding a Lantus insulin glargine injection pen, pointing the needle end left. The thumb is positioned to dial the dose on the pen's numbered scale, indicating dose adjustment.*

FDA Label Image

Lantus 29

Instructional illustration showing how to hold the Lantus insulin glargine injection pen. The image depicts a correct grip with the thumb pressing the dose button and a close-up showing proper positioning of the thumb on the dose selector, accompanied by a crossed-out incorrect grip for comparison.*

FDA Label Image

Lantus 30

An instructional illustration showing a person holding a Lantus insulin glargine injection pen subcutaneously with one hand. The diagram highlights holding the pen in place for 10 seconds after injection, indicated by a clock icon, to ensure proper delivery of the 100 units/mL solution.*

FDA Label Image

Lantus 31

An instructional illustration showing how to attach the needle cap to a Lantus (insulin glargine) 100 units/mL injection pen. The image depicts a hand holding the pen and another hand attaching the needle cover with an arrow indicating the motion direction.*

FDA Label Image

Lantus 32

An instructional illustration showing the use of a Lantus insulin glargine injection pen. The image depicts hands holding the pen, one turning the dial to select the dose while the other pushes the injection button to administer the subcutaneous injection.*

FDA Label Image

Lantus 33

An instructional illustration showing two hands: one removing a cap or seal from a bottle and the other holding a small vial or ampule above the bottle opening, with a curved arrow indicating the vial should be inserted or poured into the bottle.*

FDA Label Image

Lantus 34

An instructional diagram showing hands assembling a Lantus insulin glargine injection pen. The image illustrates connecting the pen body to the cartridge holder with an arrow indicating the direction to attach the parts before use.*

FDA Label Image

Lantus 35

Lantus 100 units/mL (U-100) insulin glargine injection packaging label from sanofi-aventis U.S. LLC. The label shows it is for subcutaneous injection only and includes warnings not to mix with other insulins and to use with U-100 syringes. The carton indicates a 10 mL multi-dose vial with storage instructions and dosage administration information.*

FDA Label Image

Lantus 36

Lantus SoloStar insulin glargine injection 100 units/mL (U-100) carton label from sanofi-aventis U.S. LLC. Contains five 3 mL prefilled pens for subcutaneous injection. The label includes instructions to not mix with other insulins and notes that needles are not included. A photo of the SoloStar pen is shown on the packaging with purple accents and dosage window.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.